Wanbury
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Wanbury Limited's board passed a circular resolution on July 15, 2026, approving the early redemption in full of its 12.5% secured, guaranteed, non‑convertible debentures. The NCDs, originally issued in two tranches in February and October 2025 with a maturity date of February 28, 2030, have an outstanding principal of ₹180 crore. The company said the exact early redemption date will be mutually agreed with debenture holders and will occur prior to the original maturity, while the record date for the redemption was set as June 20, 2026. The repayment effectively eliminates a large chunk of Wanbury’s debt ahead of schedule.
Powered by Tijori
Wanbury Limited's board passed a circular resolution on July 15, 2026, approving the early redemption in full of its 12.5% secured, guaranteed, non‑convertible debentures. The NCDs, originally issued in two tranches in February and October 2025 with a maturity date of February 28, 2030, have an outstanding principal of ₹180 crore. The company said the exact early redemption date will be mutually agreed with debenture holders and will occur prior to the original maturity, while the record date for the redemption was set as June 20, 2026. The repayment effectively eliminates a large chunk of Wanbury’s debt ahead of schedule.
Powered by Tijori
Catalyst Trusteeship, acting as debenture trustee, released a pledge on 85.2 lakh equity shares of Wanbury Limited held by Expert Chemicals (India) Private Limited. The release took effect on July 6, 2026, reducing the encumbered stake with the trustee from 34.93% of total voting capital to 10.54%.
Powered by Tijori
Catalyst Trusteeship, acting as debenture trustee, released a pledge on 85.2 lakh equity shares of Wanbury Limited held by Expert Chemicals (India) Private Limited. The release took effect on July 6, 2026, reducing the encumbered stake with the trustee from 34.93% of total voting capital to 10.54%.
Powered by Tijori
Wanbury Ltd. has received a successful quality inspection outcome from Australia's Therapeutic Goods Administration (TGA) at its API manufacturing site in Tanuku, Andhra Pradesh. The clearance brings the site closer to receiving a GMP certificate, which would enable the company to ship three additional active pharmaceutical ingredients to the Australian market. The company separately noted that its Patalganga site already received a GMP certificate from South Korea's MFDS following an inspection in April 2026, a milestone previously disclosed. Wanbury said it remains in cGMP compliance and committed to continual improvement across its manufacturing operations.
Powered by Tijori
Wanbury Ltd. has received a successful quality inspection outcome from Australia's Therapeutic Goods Administration (TGA) at its API manufacturing site in Tanuku, Andhra Pradesh. The clearance brings the site closer to receiving a GMP certificate, which would enable the company to ship three additional active pharmaceutical ingredients to the Australian market. The company separately noted that its Patalganga site already received a GMP certificate from South Korea's MFDS following an inspection in April 2026, a milestone previously disclosed. Wanbury said it remains in cGMP compliance and committed to continual improvement across its manufacturing operations.
Powered by Tijori
June 10 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - TANUKU API SITE COMPLETES TGA QUALITY INSPECTION
WANBURY - GMP CERTIFICATE TO ENABLE WANBURY TO SHIP 3 ADDITIONAL APIS
Source text: ID:nNSEGqpxY
Further company coverage: WANB.NS
(([email protected];))
June 10 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - TANUKU API SITE COMPLETES TGA QUALITY INSPECTION
WANBURY - GMP CERTIFICATE TO ENABLE WANBURY TO SHIP 3 ADDITIONAL APIS
Source text: ID:nNSEGqpxY
Further company coverage: WANB.NS
(([email protected];))
June 9 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - EXPANDED REGULATORY SUBMISSION FOR NEW ACTIVE PHARMACEUTICAL INGREDIENTS
WANBURY LTD - FOR DIPHENHYDRAMINE HCL, COMPANY SUBMITTED DMF TO MALAYSIA AND SINGAPORE
WANBURY - TO SUBMIT DMFS FOR PAROXETINE HCL IN KOREA AND LATIN AMERICA
Source text: ID:nBSE6ZP8yc
Further company coverage: WANB.NS
(([email protected];;))
June 9 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - EXPANDED REGULATORY SUBMISSION FOR NEW ACTIVE PHARMACEUTICAL INGREDIENTS
WANBURY LTD - FOR DIPHENHYDRAMINE HCL, COMPANY SUBMITTED DMF TO MALAYSIA AND SINGAPORE
WANBURY - TO SUBMIT DMFS FOR PAROXETINE HCL IN KOREA AND LATIN AMERICA
Source text: ID:nBSE6ZP8yc
Further company coverage: WANB.NS
(([email protected];;))
April 28 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - PATALGANGA SITE HAS COMPLETED KOREA FDA REGULATORY INSPECTION SUCCESSFULLY
Source text: ID:nBSEcbw68G
Further company coverage: WANB.NS
(([email protected];))
April 28 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - PATALGANGA SITE HAS COMPLETED KOREA FDA REGULATORY INSPECTION SUCCESSFULLY
Source text: ID:nBSEcbw68G
Further company coverage: WANB.NS
(([email protected];))
March 24 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - LAUNCHES CORIMINIC CPM DROPS FOR PEDIATRIC USE
WANBURY LTD - LAUNCHES CORIMINIC NS NASAL DROPS FOR CHILDREN
Source text: ID:nNSELc6Vx
Further company coverage: WANB.NS
(([email protected];))
March 24 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - LAUNCHES CORIMINIC CPM DROPS FOR PEDIATRIC USE
WANBURY LTD - LAUNCHES CORIMINIC NS NASAL DROPS FOR CHILDREN
Source text: ID:nNSELc6Vx
Further company coverage: WANB.NS
(([email protected];))
March 12 (Reuters) - Wanbury Ltd WANB.NS:
RECEIVES SERTRALINE FORM II APPROVAL FROM ANVISA, BRAZIL
RECEIVES APPROVAL FOR SPECIAL GRADE METFORMIN
Source text: ID:nBSE3w4BB
Further company coverage: WANB.NS
(([email protected];))
March 12 (Reuters) - Wanbury Ltd WANB.NS:
RECEIVES SERTRALINE FORM II APPROVAL FROM ANVISA, BRAZIL
RECEIVES APPROVAL FOR SPECIAL GRADE METFORMIN
Source text: ID:nBSE3w4BB
Further company coverage: WANB.NS
(([email protected];))
Jan 28 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - LAUNCHES COMMERCIAL PRODUCTION OF ANAESTHETIC API
WANBURY LTD - NEW API TO GENERATE 180 MILLION RUPEES IN Q4 FY 2025-26
Source text: ID:nNSEbPzctS
Further company coverage: WANB.NS
(([email protected];))
Jan 28 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - LAUNCHES COMMERCIAL PRODUCTION OF ANAESTHETIC API
WANBURY LTD - NEW API TO GENERATE 180 MILLION RUPEES IN Q4 FY 2025-26
Source text: ID:nNSEbPzctS
Further company coverage: WANB.NS
(([email protected];))
** Wanbury's shares WANB.NS rise 9%, set for fifth straight session of gains
** Pharma co to launch two new products for formulation, including iron tablets and Ketamine
** Over 255,000 shares traded, 1.6x WANB's 30-day avg
** Stock has surged ~41% in March vs a ~10% rise in Nifty pharma index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Wanbury's shares WANB.NS rise 9%, set for fifth straight session of gains
** Pharma co to launch two new products for formulation, including iron tablets and Ketamine
** Over 255,000 shares traded, 1.6x WANB's 30-day avg
** Stock has surged ~41% in March vs a ~10% rise in Nifty pharma index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Feb 12 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - TO ISSUE NCDS UP TO 2 BILLION RUPEES
Source text: ID:nBSE6vRkTp
Further company coverage: WANB.NS
(([email protected];))
Feb 12 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - TO ISSUE NCDS UP TO 2 BILLION RUPEES
Source text: ID:nBSE6vRkTp
Further company coverage: WANB.NS
(([email protected];))
Jan 3 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - COMPLETES ANVISA AUDIT AT TANUKU PLANT
WANBURY - FULL-FLEDGED MANUFACTURING OPERATIONS STARTED AT TANUKU PLANT
Source text: ID:nBSEbxM8RV
Further company coverage: WANB.NS
(([email protected];))
Jan 3 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - COMPLETES ANVISA AUDIT AT TANUKU PLANT
WANBURY - FULL-FLEDGED MANUFACTURING OPERATIONS STARTED AT TANUKU PLANT
Source text: ID:nBSEbxM8RV
Further company coverage: WANB.NS
(([email protected];))
Dec 20 (Reuters) - Wanbury Ltd WANB.NS:
TANUKU PLANT COMPLETES ANVISA INSPECTION
INSPECTION COMPLETED WITH ZERO OBSERVATIONS FOR 5 APIS
Source text: ID:nBSE1W24Ym
Further company coverage: WANB.NS
(([email protected];;))
Dec 20 (Reuters) - Wanbury Ltd WANB.NS:
TANUKU PLANT COMPLETES ANVISA INSPECTION
INSPECTION COMPLETED WITH ZERO OBSERVATIONS FOR 5 APIS
Source text: ID:nBSE1W24Ym
Further company coverage: WANB.NS
(([email protected];;))
** Shares of Wanbury WANB.NS rise 4.45% to 218.49 rupees
** Pharma co gets establishment inspection report (EIR) from U.S. FDA for its Maharashtra facility
** Inspection classified as "no action indicated" with "zero Form-483 observations"
** Zero Form-483 observations indicate the facility is in acceptable state of compliance with current good manufacturing practices
** Stock up about 17% this week, on course for best weekly performance since September 2023 - NSE data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Wanbury WANB.NS rise 4.45% to 218.49 rupees
** Pharma co gets establishment inspection report (EIR) from U.S. FDA for its Maharashtra facility
** Inspection classified as "no action indicated" with "zero Form-483 observations"
** Zero Form-483 observations indicate the facility is in acceptable state of compliance with current good manufacturing practices
** Stock up about 17% this week, on course for best weekly performance since September 2023 - NSE data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Wanbury Ltd WANB.NS rise as much as 5%, before trimming gains to trade 4.2% higher
** Pharma co said United States Food and Drug Administration completed inspection at co's Patalganga site in Maharashtra with zero observations
** Stock set for best one-day rise in a month
** Stock set to rise for a fifth straight quarter, gaining nearly 4x in the last four quarters
** Trading vol is 1.5x the 30-day daily avg
** Stock up ~31% in 2024 so far, after gaining 2.5x in 2023
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
** Shares of Wanbury Ltd WANB.NS rise as much as 5%, before trimming gains to trade 4.2% higher
** Pharma co said United States Food and Drug Administration completed inspection at co's Patalganga site in Maharashtra with zero observations
** Stock set for best one-day rise in a month
** Stock set to rise for a fifth straight quarter, gaining nearly 4x in the last four quarters
** Trading vol is 1.5x the 30-day daily avg
** Stock up ~31% in 2024 so far, after gaining 2.5x in 2023
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
May 16 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD MARCH-QUARTER CONSOL PAT 336.3 MILLION RUPEES VERSUS 10.2 MILLION RUPEES
WANBURY LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.39 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSEzHxMk
Further company coverage: WANB.NS
(([email protected];;))
May 16 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD MARCH-QUARTER CONSOL PAT 336.3 MILLION RUPEES VERSUS 10.2 MILLION RUPEES
WANBURY LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.39 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSEzHxMk
Further company coverage: WANB.NS
(([email protected];;))
Oct 20 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY LTD SEPT-QUARTER CONSOL PAT 73.6 MILLION RUPEES VERSUS LOSS 8.9 MILLION RUPEES YEAR AGO
WANBURY LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.44 BILLION RUPEES VERSUS 1.24 BILLION RUPEES YEAR AGO
WANBURY LTD - APPROVED ISSUE OF CONVERTIBLE WARRANTS WORTH UPTO 240 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WANB.NS
(([email protected];))
Oct 20 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY LTD SEPT-QUARTER CONSOL PAT 73.6 MILLION RUPEES VERSUS LOSS 8.9 MILLION RUPEES YEAR AGO
WANBURY LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.44 BILLION RUPEES VERSUS 1.24 BILLION RUPEES YEAR AGO
WANBURY LTD - APPROVED ISSUE OF CONVERTIBLE WARRANTS WORTH UPTO 240 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WANB.NS
(([email protected];))
Oct 17 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSEbV0Sf3
Further company coverage: WANB.NS
(([email protected];))
Oct 17 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSEbV0Sf3
Further company coverage: WANB.NS
(([email protected];))
Aug 11 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY JUNE-QUARTER CONSOL PAT 46.9 MILLION RUPEES VERSUS LOSS 72.4 MILLION RUPEES
WANBURY JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSE9qKvsj
Further company coverage: WANB.NS
(([email protected];;))
Aug 11 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY JUNE-QUARTER CONSOL PAT 46.9 MILLION RUPEES VERSUS LOSS 72.4 MILLION RUPEES
WANBURY JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSE9qKvsj
Further company coverage: WANB.NS
(([email protected];;))
July 6 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER ISSUE OF NONCONVERTIBLE DEBENTURES ON PRIVATE PLACEMENT BASIS
Source text for Eikon: ID:nBSE3Kv3vR
Further company coverage: WANB.NS
(([email protected];))
July 6 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER ISSUE OF NONCONVERTIBLE DEBENTURES ON PRIVATE PLACEMENT BASIS
Source text for Eikon: ID:nBSE3Kv3vR
Further company coverage: WANB.NS
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Wanbury do?
Wanbury Limited is a prominent Indian pharmaceutical company ranked among the top 50 in the country. Specializing in API sales globally and domestic formulations, Wanbury has a significant presence in the industry.
Who are the competitors of Wanbury?
Wanbury major competitors are Lincoln Pharma, Syncom Formulations, Bharat Parenterals, Jagsonpal Pharma, Anuh Pharma, Fredun Pharma, Zim Laboratories. Market Cap of Wanbury is ₹1,174 Crs. While the median market cap of its peers are ₹1,207 Crs.
Is Wanbury financially stable compared to its competitors?
Wanbury seems to be less financially stable compared to its competitors. Altman Z score of Wanbury is 3.98 and is ranked 6 out of its 8 competitors.
Does Wanbury pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Wanbury latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Wanbury allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable
How strong is Wanbury balance sheet?
Balance sheet of Wanbury is strong. But short term working capital might become an issue for this company.
Is the profitablity of Wanbury improving?
The profit is oscillating. The profit of Wanbury is ₹66.14 Crs for TTM, ₹30.53 Crs for Mar 2025 and ₹55.96 Crs for Mar 2024.
Is the debt of Wanbury increasing or decreasing?
Yes, The net debt of Wanbury is increasing. Latest net debt of Wanbury is ₹148 Crs as of Mar-25. This is greater than Mar-24 when it was ₹97.6 Crs.
Is Wanbury stock expensive?
Yes, Wanbury is expensive. Latest PE of Wanbury is 27.98, while 3 year average PE is 18.48. Also latest EV/EBITDA of Wanbury is 12.77 while 3yr average is 11.0.
Has the share price of Wanbury grown faster than its competition?
Wanbury has given better returns compared to its competitors. Wanbury has grown at ~34.28% over the last 8yrs while peers have grown at a median rate of 16.13%
Is the promoter bullish about Wanbury?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Wanbury is 43.02% and last quarter promoter holding is 43.07%
Are mutual funds buying/selling Wanbury?
There is Insufficient data to gauge this.